159 related articles for article (PubMed ID: 23649759)
1. Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo.
Jiang HL; Jin JZ; Wu D; Xu D; Lin GF; Yu H; Ma DY; Liang J
Mol Biol Rep; 2013 Jul; 40(7):4203-9. PubMed ID: 23649759
[TBL] [Abstract][Full Text] [Related]
2. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
[TBL] [Abstract][Full Text] [Related]
3. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
[TBL] [Abstract][Full Text] [Related]
4. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice.
Chen X; Hu X; Hu J; Qiu Z; Yuan M; Zheng G
Mol Pharm; 2020 Mar; 17(3):738-747. PubMed ID: 31904241
[TBL] [Abstract][Full Text] [Related]
5. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
6. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
[TBL] [Abstract][Full Text] [Related]
7. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
8. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.
Bu R; Uddin S; Bavi P; Hussain AR; Al-Dayel F; Ghourab S; Ahmed M; Al-Kuraya KS
Lab Invest; 2011 Jan; 91(1):124-37. PubMed ID: 20661229
[TBL] [Abstract][Full Text] [Related]
9. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
You H; Ding W; Dang H; Jiang Y; Rountree CB
Hepatology; 2011 Sep; 54(3):879-89. PubMed ID: 21618573
[TBL] [Abstract][Full Text] [Related]
10. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW
Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320
[TBL] [Abstract][Full Text] [Related]
11. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
[TBL] [Abstract][Full Text] [Related]
12. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anticancer effects of triptolide and celastrol, two main compounds from thunder god vine.
Jiang QW; Cheng KJ; Mei XL; Qiu JG; Zhang WJ; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Zhang X; Lv M; Chen MW; Wei X; Shi Z
Oncotarget; 2015 Oct; 6(32):32790-804. PubMed ID: 26447544
[TBL] [Abstract][Full Text] [Related]
14. Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.
Yin Y; Guo J; Teng F; Yu L; Jiang Y; Xie K; Jiang M; Fang J
Drug Des Devel Ther; 2019; 13():4173-4184. PubMed ID: 31849449
[TBL] [Abstract][Full Text] [Related]
15. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
[TBL] [Abstract][Full Text] [Related]
16. Anticancer and Antiangiogenic Activities of Novel α-Mangostin Glycosides in Human Hepatocellular Carcinoma Cells via Downregulation of c-Met and HIF-1α.
Kim SM; Han JM; Le TT; Sohng JK; Jung HJ
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32516967
[TBL] [Abstract][Full Text] [Related]
17. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.
Liu Y; Tan J; Ou S; Chen J; Chen L
Invest New Drugs; 2020 Feb; 38(1):60-69. PubMed ID: 30929159
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma.
Du Z; Caenepeel S; Shen Y; Rex K; Zhang Y; He Y; Tang ET; Wang O; Zhong W; Zhou H; Huang J; Huang E; Hu L; Coxon A; Zhang M
Mol Cancer Ther; 2016 Jun; 15(6):1227-37. PubMed ID: 27196749
[TBL] [Abstract][Full Text] [Related]
20. Celastrol Enhances the Anti-Liver Cancer Activity of Sorafenib.
Zhang R; Chen Z; Wu SS; Xu J; Kong LC; Wei P
Med Sci Monit; 2019 Jun; 25():4068-4075. PubMed ID: 31152143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
